Texas Roadhouse earnings missed by $0.05, revenue topped estimates
Natera, Inc. (NASDAQ:NTRA) Executive Chairman Matthew Rabinowitz sold 1,718 shares of common stock on July 28, 2025, at a price of $139.8083, according to a Form 4 filing with the Securities and Exchange Commission. The total value of the transaction amounted to $240,190. The molecular diagnostics company, currently valued at $19.2 billion, maintains strong financial health according to InvestingPro analysis, with liquid assets well exceeding short-term obligations.
Following the transaction, Rabinowitz directly owns 2,360,852 shares of Natera, Inc. The filing also indicates that Rabinowitz indirectly owns 30,000 shares through a spouse. The stock has shown significant volatility, with a beta of 1.73, though it maintains a conservative debt-to-equity ratio of 0.16. For deeper insights into Natera’s financial metrics and additional InvestingPro Tips, subscribers can access the comprehensive Pro Research Report.
The sale was to satisfy tax obligations related to vested Restricted Stock Units (RSUs) under a pre-arranged 10b5-1 trading plan.
In other recent news, Natera has reported significant achievements and updates that are capturing investor attention. Natera’s first-quarter performance in 2025 was robust, with the company surpassing sales expectations by 13%, driven by a 5% increase in core sales and other favorable factors. This strong performance led RBC Capital Markets to maintain an Outperform rating with a price target of $251, while TD Cowen raised its price target to $200, citing impressive sales growth and increased clinical volumes for the Signatera product. Medicare has expanded coverage for Natera’s Signatera MRD assay, now including a broader range of cancers, which is expected to positively impact reimbursement rates.
Additionally, Evercore ISI initiated coverage on Natera with an Outperform rating and a $170 price target, indicating a 20% potential upside. Meanwhile, Leerink Partners reiterated its Outperform rating with a $220 price target, highlighting the recent Medicare coverage for Natera’s WGS Signatera assay. This expanded coverage follows a successful bridging study and is seen as a positive development for the company’s reimbursement prospects. RBC Capital Markets analysts have expressed confidence in Natera’s financial guidance for fiscal year 2025, emphasizing effective commercial execution and Medicare Advantage expansion as key factors in improving profit margins.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.